A.F.H. Stalenhoef

5.5k total citations · 1 hit paper
44 papers, 2.2k citations indexed

About

A.F.H. Stalenhoef is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, A.F.H. Stalenhoef has authored 44 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Surgery, 18 papers in Endocrinology, Diabetes and Metabolism and 13 papers in Cancer Research. Recurrent topics in A.F.H. Stalenhoef's work include Lipoproteins and Cardiovascular Health (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cancer, Lipids, and Metabolism (10 papers). A.F.H. Stalenhoef is often cited by papers focused on Lipoproteins and Cardiovascular Health (20 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (14 papers) and Cancer, Lipids, and Metabolism (10 papers). A.F.H. Stalenhoef collaborates with scholars based in Netherlands, United States and Vietnam. A.F.H. Stalenhoef's co-authors include Pierre N.M. Demacker, TJ Smilde, M van Linde-Sibenius Trip, Sanne van Wissen, P.M.J. Stuyt, John P. Kane, R J Havel, A. van ‘t Laar, Bart Jan Kullberg and Mihai G. Netea and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

A.F.H. Stalenhoef

42 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial

2001 704 citations TJ Smilde, Sanne van Wissen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.F.H. Stalenhoef Netherlands	21	1.2k	777	590	380	350	44	2.2k
John W. Gaubatz United States	27	1.5k 1.2×	710 0.9×	450 0.8×	658 1.7×	529 1.5×	42	2.7k
Ichiro Michishita Japan	22	1.1k 0.9×	546 0.7×	457 0.8×	268 0.7×	258 0.7×	88	1.9k
Jonathan L. Isaacsohn United States	22	1.5k 1.2×	725 0.9×	582 1.0×	289 0.8×	226 0.6×	50	2.4k
Takamitsu Nakano Japan	23	848 0.7×	1.3k 1.7×	710 1.2×	546 1.4×	315 0.9×	50	2.2k
Gabriele Bittolo Bon Italy	20	902 0.7×	870 1.1×	451 0.8×	228 0.6×	304 0.9×	43	2.3k
Allen D. Cooper United States	26	967 0.8×	783 1.0×	544 0.9×	298 0.8×	593 1.7×	63	2.1k
J.G. Brook Israel	23	787 0.6×	480 0.6×	479 0.8×	137 0.4×	247 0.7×	76	1.7k
D.W. Erkelens Netherlands	32	1.2k 1.0×	1.5k 1.9×	788 1.3×	403 1.1×	497 1.4×	85	2.9k
J C Fruchart France	28	1.4k 1.1×	1.3k 1.7×	491 0.8×	599 1.6×	849 2.4×	87	2.7k
Patricia J. Blanche United States	28	1.3k 1.1×	1.5k 2.0×	475 0.8×	520 1.4×	618 1.8×	52	2.8k

Countries citing papers authored by A.F.H. Stalenhoef

Since Specialization

Citations

This map shows the geographic impact of A.F.H. Stalenhoef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.F.H. Stalenhoef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.F.H. Stalenhoef more than expected).

Fields of papers citing papers by A.F.H. Stalenhoef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.F.H. Stalenhoef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.F.H. Stalenhoef. The network helps show where A.F.H. Stalenhoef may publish in the future.

Co-authorship network of co-authors of A.F.H. Stalenhoef

This figure shows the co-authorship network connecting the top 25 collaborators of A.F.H. Stalenhoef. A scholar is included among the top collaborators of A.F.H. Stalenhoef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.F.H. Stalenhoef. A.F.H. Stalenhoef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kastelein, John J.P., Fatima Akdim, E.S.G. Stroes, et al.. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008). New England Journal of Medicine. 358(18). 10 indexed citations

Himbergen, Thomas M. van, Lambertus J.H. van Tits, Mark Roest, & A.F.H. Stalenhoef. (2006). The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine.. PubMed. 64(2). 34–8. 46 indexed citations

Himbergen, Thomas M. van, Lambertus J.H. van Tits, Hieronymus A.M. Voorbij, et al.. (2005). The effect of statin therapy on plasma high‐density lipoprotein cholesterol levels is modified by paraoxonase‐1 in patients with familial hypercholesterolaemia. Journal of Internal Medicine. 258(5). 442–449. 12 indexed citations

Schouten, E.G., et al.. (2001). Serum carotenoids, α-tocopherol and mortality risk in a prospective study among Dutch elderly. International Journal of Epidemiology. 30(1). 136–143. 76 indexed citations

Stalenhoef, A.F.H., M.P.C. Hectors, & Pierre N.M. Demacker. (2001). Effect of plant sterol‐enriched margarine on plasma lipids and sterols in subjects heterozygous for phytosterolaemia. Journal of Internal Medicine. 249(2). 163–166. 25 indexed citations

Smilde, TJ, et al.. (2001). Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. The Lancet. 357(9256). 577–581. 704 indexed citations breakdown →

Graaf, Jacqueline de, et al.. (2000). Familial Chylomicronemia Caused by a Novel Type of Mutation in the APOE-CI-CIV-CII Gene Cluster Encompassing Both the APOCII Gene and the First APOCIV Gene Mutation: APOCII-CIVNijmegen. Biochemical and Biophysical Research Communications. 273(3). 1084–1087. 7 indexed citations

Patel, Shailendra B., Gerald Salen, Hideki Hidaka, et al.. (1998). Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21.. Journal of Clinical Investigation. 102(5). 1041–1044. 144 indexed citations

Netea, Mihai G., Pierre N.M. Demacker, Bart Jan Kullberg, et al.. (1996). Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.. Journal of Clinical Investigation. 97(6). 1366–1372. 188 indexed citations

10.

Kleinveld, Henne A., Heidi L.M. Hak-Lemmers, M.P.C. Hectors, et al.. (1994). Antioxidative intervention alone does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis. 109(1-2). 54–55. 1 indexed citations

11.

Knijff, Peter de, Arn M. J. M. van den Maagdenberg, A.F.H. Stalenhoef, et al.. (1991). Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.. Journal of Clinical Investigation. 88(2). 643–655. 84 indexed citations

12.

Stuyt, P.M.J., B.J. Brenninkmeijer, Pierre N.M. Demacker, et al.. (1991). Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins. in angiographically assessed coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation. 51(5). 425–435. 26 indexed citations

13.

Hoogerbrugge, Nicoline, et al.. (1990). The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. Journal of Internal Medicine. 228(3). 261–266. 31 indexed citations

14.

Mol, M.J.T.M., P.M.J. Stuyt, Pierre N.M. Demacker, & A.F.H. Stalenhoef. (1990). The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.. PubMed. 36(3-4). 182–90. 7 indexed citations

15.

Fojo, S S, J. L. de Gennes, Ulrike Beisiegel, et al.. (1990). Molecular Genetics of ApoC-II and Lipoprotein Lipase Deficiency. Advances in experimental medicine and biology. 285. 329–333. 13 indexed citations

16.

Stuyt, P.M.J., M.J.T.M. Mol, A.F.H. Stalenhoef, Pierre N.M. Demacker, & A. van ‘t Laar. (1990). Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).. PubMed. 88(1N). 42N–45N. 11 indexed citations

17.

Maagdenberg, Arn M. J. M. van den, Peter de Knijff, A.F.H. Stalenhoef, et al.. (1989). Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4. Biochemical and Biophysical Research Communications. 165(2). 851–857. 48 indexed citations

18.

Smeets, Hubert J.M., et al.. (1988). Identification of apolipoprotein E polymorphism by using synthetic oligonucleotides.. Journal of Lipid Research. 29(9). 1231–1237. 17 indexed citations

19.

Stalenhoef, A.F.H., et al.. (1987). Apolipoprotein CII (apo CII) gene expression defect in an individual with familial apo CII deficiency. Biochemical and Biophysical Research Communications. 148(1). 320–328. 7 indexed citations

20.

Stalenhoef, A.F.H., Pierre N.M. Demacker, J. A. Lutterman, & A. van ‘t Laar. (1986). Plasma lipoproteins, apolipoproteins, and triglyceride metabolism in familial hypertriglyceridemia.. Arteriosclerosis An Official Journal of the American Heart Association Inc. 6(4). 387–394. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact